SCHEMBL351705

SCHEMBL351705

O=C(O)c1cc(Nc2ccccc2)c(C(=O)O)cc1Nc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.79
GFER P55789 1/20 0.79
NGLY1 Q96IV0 1/20 0.79
FABP4 P15090 1/20 0.66
AKR1C3 P42330 10/20 0.64
AKR1C2 P52895 10/20 0.64
CTSV O60911 2/20 0.60
CTSL P07711 2/20 0.60
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
THRB P10828 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ALOX15 P16050 1/20 0.52
MAPK8 P45983 1/20 0.51
PTGS1 P23219 2/20 0.50
PTGS2 P35354 1/20 0.50
TAS2R14 Q9NYV8 1/20 0.50
DHODH Q02127 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9172301 0.98 MAPT (0.76) MAPTGFERNGLY1FABP4AKR1C3
Hydrochloric Acid SCHEMBL28298843 0.92 MAPT (0.73) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL8833788 0.91 MAPT (0.67) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL8002116 0.91 MAPT (0.67) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL708364 0.89 MAPT (0.65) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL11647944 0.89 MAPT (0.65) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL14598924 0.89 MAPT (0.65) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL14349651 0.89 GFER (0.65) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL3234696 0.89 MAPT (0.65) MAPTGFERNGLY1FABP4AKR1C3
SCHEMBL13271182 0.89 MAPT (0.65) MAPTGFERNGLY1FABP4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 868 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042084-A1 SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP GENERAL ELECTRIC TECHNOLOGY GMBH (CH) 2026-02-12 US claimed
EP-4680369-A1 SYSTEMS FOR CARBON DIOXIDE CAPTURE USING FUNCTIONALIZED SORBENTS AND WATER MANAGEMENT GE Vernova Technology GmbH (CH) 2026-01-21 EP claimed
WO-2025238576-A1 SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION Nuovo Pignone Tecnologie – S.r.l. (IT) 2025-11-20 WO claimed
US-20250354659-A1 SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION NUOVO PIGNONE TECNOLOGIE – S R L (IT) 2025-11-20 US claimed
CN-117720824-B Improved method for manufacturing quinacridone solid solution pigment 温州金源新材料科技有限公司 2025-06-17 CN claimed
EP-4556112-A2 SORBENT COMPOSITIONS, SYSTEMS, AND METHODS General Electric Technology GmbH (CH) 2025-05-21 EP claimed
CN-119869460-A Sorbent compositions, systems, and methods 通用电气技术有限公司 2025-04-25 CN claimed
US-12263464-B2 Method for in-situ synthesis of metal organic frameworks (MOFs), covalent organic frameworks (COFs) and zeolite imidazolate frameworks (ZIFs), and applications thereof DESICCANT ROTORS INTERNATIONAL PRIVATE LIMITED (IN) 2025-04-01 US claimed
CN-119463525-A Preparation method of quinacridone pigment 宇虹颜料股份有限公司 2025-02-18 CN claimed
CN-119060559-A Beta-quinacridone organic pigment and preparation method thereof 绍兴上虞新利化工有限公司 2024-12-03 CN claimed
WO-1992009558-A1 METHOD OF PREPARING 2,5-DI(PHENYLAMINO)TEREPHTHALIC ACID AND ITS DIALKYL ESTERS AS HIGH-PURITY PRODUCTS HOECHST AKTIENGESELLSCHAFT (DE) 1992-06-11 WO claimed
US-4956464-A Cyclization, dehydrogenation in the vapor phase or solid phase in the presence of an oxidizer BASF AKTIENGESELLSCHAFT (DE) 1990-09-11 US claimed
US-4758665-A Process for preparing high-hiding gamma-modification of unsubstituted linear transquinacridone HOECHST AKTIENGESELLSCHAFT (DE) 1988-07-19 US claimed
EP-0142066-B1 COVERING GAMMA MODIFICATION OF A NON SUBSTITUTED LINEAR TRANS-QUINACRIDONE HOECHST AKTIENGESELLSCHAFT (DE) 1987-11-25 EP claimed
EP-0142066-A2 Covering gamma modification of a non substituted linear trans-quinacridone HOECHST AKTIENGESELLSCHAFT (DE) 1985-05-22 EP claimed
EP-0001613-B1 PROCESS FOR PREPARING LINEAR TRANS-QUINACRIDONE IN GAMMA-CRYSTAL MODIFICATION HOECHST AKTIENGESELLSCHAFT (DE) 1982-09-29 EP claimed
US-4212975-A Process for the manufacture of the gamma-crystal modification of linear trans-quinacridone HOECHST AKTIENGESELLSCHAFT (DE) 1980-07-15 US claimed
EP-0001613-A1 Process for preparing linear trans-quinacridone in gamma-crystal modification HOECHST AKTIENGESELLSCHAFT (DE) 1979-05-02 EP claimed
US-4100162-A Process for preparing gamma quinacridone from polyphosphoric acid and alcohol HARMON COLORS (US) 1978-07-11 US claimed
US-4064129-A Process for making quinacridone and its derivatives HARMON COLORS CORPORATION (US) 1977-12-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042084-A1 SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP SRMS, TYRO3, SELE MAPT 1454/4885GFER 355/4885NGLY1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.